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The discovery that adult somatic cells can be induced to become pluripotent by overexpres-
sion of a few key transcription factors provides an exciting new window into the basic biology of 
pluripotency and differentiation.The discovery 3 years ago that adult 
somatic cells can be induced to become 
pluripotent stem cells, so-called iPS cells, 
by overexpression of a few key transcrip-
tion factors (Takahashi and Yamanaka, 
2006) generated much excitement 
because of the potential therapeutic 
applications of these cells (reviewed in 
Yamanaka, 2009). Efforts are underway 
in many laboratories to apply iPS cell 
technology to modeling diseases in vitro 
and to developing tissue-replacement 
therapies. To fulfill the therapeutic prom-
ise of iPS cells, a major research focus 
has been to improve the efficiency and 
completeness of reprogramming back to 
a pluripotent state. Other research ave-
nues include finding ways to deliver the 
genes encoding the reprogramming fac-
tors without using viruses, thus avoiding 
the need for genomic integration, and 616 Cell 138, August 21, 2009 ©2009 Elseviecompiling panels of iPS cells derived 
from patients with different diseases in 
order to drive their in vitro differentiation 
into the cell type affected in the disease. 
The generation of iPS cells, however, 
may also be valuable for gaining insights 
into the basic biology of pluripotency 
and differentiation.
The mechanisms by which somatic 
cells are reprogrammed back to a pluri-
potent state are largely unknown. During 
the reprogramming process, cells often 
get “trapped” in partially reprogrammed 
states due to inefficient DNA demethy-
lation or incomplete repression/ectopic 
expression of lineage-specific transcrip-
tion factors (Mikkelsen et al., 2008). The 
contribution of each reprogramming fac-
tor is not well understood, but c-Myc is 
thought to act early to repress somatic cell 
genes (Sridharan et al., 2009). Binding of Figure 1. The iPS Cell Assay
The epigenetic reprogramming that occurs in vivo in the fertilized egg or in primordial germ cells (PGCs) 
may have a parallel with the molecular events underpinning iPS cell generation in vitro. The derivation of 
iPS cells may provide a gain-of-function assay for analyzing and quantifying pluripotency. The iPS cell 
assay is reproducible, quantitative, and can be modulated by various conditions. This assay may provide 
new insights into the roles of chromatin factors, transcriptional networks, and microRNAs in pluripotency 
and in lineage commitment decisions during differentiation. The iPS cell assay can also be used to iden-
tify the mechanisms that “lock-in” the state of differentiated cells and prevent dedifferentiation. r Inc.the other three reprogramming factors—
Oct4, Sox2, and Klf4—to pluripotency 
genes may be a later, rate-limiting step in 
the progression to complete reprogram-
ming (Sridharan et al., 2009). These and 
other studies are beginning to reveal the 
mechanisms that underlie the induction 
of pluripotency (reviewed in Hochedlinger 
and Plath, 2009). But can iPS cells pro-
vide insights into basic biology?
Modeling In Vivo Reprogramming
Cells developing in vivo progress from 
undifferentiated states with broad cell-
fate potential to committed states with 
restricted potential. Arguably, the gener-
ation of iPS cells represents an artificial 
experimental manipulation that “plays 
the development tape backwards” and 
therefore may not have a parallel in vivo. 
However, iPS cell generation may involve 
molecular processes that have parallels 
with fundamental events during mam-
malian development (Figure 1). One such 
event is the reprogramming of the gam-
ete pronuclei at fertilization, which leads 
to initiation of the embryonic program. 
The DNA in the sperm pronucleus is 
highly compacted and undergoes decon-
densation and demethylation under the 
influence of oocyte intracellular factors. 
Some of these same factors, most of 
which are unknown, presumably also are 
involved in the reprogramming of adult 
cell nuclei by somatic cell nuclear trans-
fer (SCNT). The mechanisms underlying 
SCNT have proven difficult to dissect, 
mostly because of the complexity and 
low reproducibility of the assay.
Later in development, primordial germ 
cells (PGCs) also undergo a process of 
reprogramming that involves genome-
wide demethylation of DNA and modifi-
cation of histones. The generation of iPS 
cells from adult somatic cells involves 
extensive epigenetic reprogramming 
that includes chromatin decondensa-
tion and DNA demethylation. Epigenetic 
reprogramming during the generation of 
iPS cells may well be mediated by mech-
anisms very different from those that 
operate during in vivo reprogramming 
in either oocytes or PGCs, and this will 
need to be carefully assessed. However, 
should there be some molecular parallels 
between epigenetic reprogramming in 
vivo and iPS cell generation in vitro, then 
the latter may provide a particularly trac-
table genetic and biochemical system 
to dissect the underlying mechanisms. 
Unlike oocytes or PGCs, which exist in 
very limited numbers in vivo, large num-
bers of cells can be reprogrammed, in a 
quantitative and reproducible manner, to 
become iPS cells in vitro.
The derivation of iPS cells also may 
be used to explore the molecular under-
pinnings of germ cell tumor develop-
ment. The transcriptional profile of 
PGCs is similar to that of embryonic 
stem (ES) cells and includes expres-
sion of Oct4, Sox2, Nanog, and other 
pluripotency-associated factors. PGCs 
do not express c-Myc but do express 
high levels of another Myc family mem-
ber, n-Myc, and n-Myc can substitute 
for c-Myc in the generation of iPS cells 
(Blelloch et al., 2007). PGCs do not 
express Klf4, which is activated dur-
ing conversion of PGCs to pluripotent 
stem cells in vitro. It will be interesting 
to determine whether acquisition of Klf4 
expression, or other molecular events 
that occur during iPS cell generation, 
play any role in the transformation of 
PGCs and the development of germ cell 
tumors.
A Gain-of-Pluripotency Assay
The derivation of iPS cells may be viewed 
as a biochemical assay for pluripotency. 
It is reproducible, quantitative, and can 
be modulated by various conditions 
including the addition of cofactors (Fig-
ure 1). Genetic manipulation of the iPS 
cell assay—such as knockdown or over-
expression of candidate genes in addi-
tion to or substituting for the four repro-
gramming factors—may allow questions 
to be asked about the molecular mecha-
nisms that underlie pluripotency during 
normal embryonic development.The initial report of iPS cell genera-
tion (Takahashi and Yamanaka, 2006) 
provided an important basic insight into 
the transcriptional networks of pluripo-
tency. Of the four factors used by Taka-
hashi and Yamanaka, Klf4 was the most 
unexpected because it is not required 
for pluripotency. It is now known that a 
redundant network composed of Klf2, 
Klf4, and Klf5 is essential for ES cell 
pluripotency and regulates many of the 
same target genes as Nanog (Jiang et al., 
2008). Also, an orphan nuclear receptor 
(estrogen-related receptor-β) required 
for ES cell self-renewal can substitute for 
c-Myc and Klf4 during the induction of 
pluripotency (Feng et al., 2009). Thus, an 
interplay between research on iPS cells 
and ES cells may accelerate our under-
standing of the basic biology of pluripo-
tency.
Another area in which the iPS cell 
assay may provide fundamental insights 
is in microRNA (miRNA) biology. The 
miRNAs miR-291-3p, miR-294, and 
miR-295, which are expressed specifi-
cally in ES cells and regulate progres-
sion of ES cells through the cell cycle, 
enhance the efficiency of pluripotency 
induction (Judson et al., 2009). Although 
it remains unclear whether these miRNAs 
have overlapping targets in ES cells and 
during reprogramming, the iPS cell assay 
provides a complementary approach for 
studying the biology of miRNAs associ-
ated with pluripotency.
Recent data from our laboratory sug-
gest that some of the mechanisms that 
maintain the open chromatin state of 
ES cells may also operate during the 
generation of iPS cells. Chd1, a chro-
matin-remodeling factor required for 
maintenance of open chromatin and 
pluripotency of ES cells, is also needed 
for the induction of pluripotency (Gas-
par-Maia et al., 2009). Therefore, the 
iPS cell assay can provide opportuni-
ties to gain insights into the functions 
of transcription factors, miRNAs, and 
chromatin-remodeling factors in pluri-
potent cells. Analogous questions may 
be asked regarding the roles of signaling 
proteins, metabolic pathways, cell-cycle 
regulators, and cytoskeletal proteins in 
pluripotency.
The iPS cell assay may be particularly 
useful as a gain-of-function assay in 
cases where loss of function of particular Cell 13genes in early embryos or ES cells would 
provide only limited insight. For example, 
the cell-cycle and metabolic pathways of 
early embryos and ES cells have unique 
characteristics. Although loss-of-func-
tion approaches to analyze these char-
acteristics may lead to lethality, the iPS 
cell assay enables their investigation 
during the reprogramming of somatic 
cells to the pluripotent state.
Beyond addressing these questions, 
the iPS cell assay provides an oppor-
tunity for structure-function studies to 
identify the relevant protein domains or 
amino acids of a particular transcription 
factor, chromatin-remodeling protein, or 
signaling protein that may be involved 
in pluripotency. It is not that such stud-
ies are impossible in early embryos or 
in ES cells, but rather that the iPS cell 
assay provides a simple complementary 
approach with which to accelerate the 
mechanistic dissection of pluripotency.
Finally, it may be possible to use varia-
tions of the iPS cell assay to gain insight 
into lineage commitment decisions. In a 
restricted number of cases, it is possible 
to convert one cell type into another by 
manipulating the expression of lineage-
specific transcription factors (reviewed 
in Zhou and Melton, 2008). Knowledge 
gained about how cells change states 
during the generation of iPS cells—
for example, how they alter chromatin 
accessibility or reprogram epigenetic 
marks—may contribute to a better 
understanding of lineage commitment 
and cell-fate switching.
Dissecting the Stability of the 
Differentiated State
In addition to providing new insights into 
the regulation of the pluripotent state, 
the iPS cell assay may be a new tool to 
probe the molecular mechanisms that 
underlie the stability of the differentiated 
state (Figure 1). Developmental biologists 
have long pondered whether a terminally 
differentiated state is reversible and 
what locks that state in place. Indeed, 
this was the motivation behind the origi-
nal SCNT experiments in amphibians 
(Gurdon, 1962). Many decades later, we 
still know little about the process of ded-
ifferentiation, which may have important 
consequences for our understanding of 
cellular transformation and tumor devel-
opment. Transformed cells may in some 8, August 21, 2009 ©2009 Elsevier Inc. 617
cases arise by dedifferentiation, that is, 
by losing markers of terminally differen-
tiated cells and acquiring stem cell-like 
properties. The iPS cell assay may shed 
light on the genes and pathways that 
“lock-in” cells in the differentiated state 
enabling them to resist dedifferentiation.
Inhibition of the tumor suppressor pro-
tein p53 facilitates the generation of iPS 
cells, suggesting that it represses dedif-
ferentiation (Zhao et al., 2008). The iPS 
cell assay can be used to study how p53 
modulates the stability of the differenti-
ated state. Other tumor suppressors, 
such as Rb or Pten, are also candidate 
repressors of dedifferentiation that can 
be investigated using the iPS cell assay. 
Lineage-specific transcription factors 
and epigenetic modifications such as 
DNA methylation or lack of H3K4 methy-
lation at certain loci also may repress 
dedifferentiation (Mikkelsen et al., 2008). 
It will be interesting to test whether inhi-
bition of miRNAs expressed in differenti-
ated cells but not in stem cells, such as 
let-7, facilitates reprogramming.
More broadly, it may be possible to 
apply the iPS cell assay to discover new 
genes that act as repressors of dedif-
ferentiation in an unbiased way using, 
for example, large-scale RNAi screens. 
Screening for repressors of dedifferen-
tiation using induction of pluripotency 
in different adult somatic cell types may 
reveal some genes that act universally 
to repress dedifferentiation, and others 
that regulate the stability of specific cell 
types. The transcriptional similarities 
between pluripotent stem cells and can-
cer cells (Wong et al., 2008) suggest that 
the iPS cell assay may provide a new 
quantitative approach for investigating 
regulation of the differentiated cell state 
and how it may be subverted in cancer.
iPS Cells in Basic Biology: Caveats
Some of these research avenues make the 
assumption that the same mechanisms 
that implement pluripotency in vivo or in 
ES cells operate during the generation of 
iPS cells in vitro. This may not necessar-
ily be so, as exemplified by the case of 
Mbd3, a subunit of the NuRD transcrip-
tional repressor complex. Mouse blasto-
cysts lacking the Mbd3 gene cannot give 
rise to ES cells but, when both alleles are 
mutated by gene targeting in preexisting 618 Cell 138, August 21, 2009 ©2009 ElsevieES cells, Mbd3 is not required for ES cell 
maintenance and propagation (Kaji et al., 
2006). That is to say, Mbd3 is required 
for reprogramming of the inner cell mass 
of the embryo to the ES cell state, but 
not for maintenance of ES cells. It will be 
interesting to see if analogous examples 
of differences between reprogramming 
and pluripotency can be identified using 
the iPS cell assay. Presumably, there will 
be mechanistic similarities between the 
two phenomena.
A further caveat is that often repro-
gramming during iPS cell generation is 
incomplete and may not faithfully repro-
duce reprogramming in vivo or the pluri-
potent state of ES cells. The presence 
of incompletely reprogrammed iPS cell 
colonies, coupled with the low efficiency 
of iPS cell generation, means that there 
is significant cell heterogeneity during 
reprogramming, with properly repro-
grammed iPS cells constituting a small 
minority of the somatic cells treated 
with reprogramming factors. This is fur-
ther complicated by the time it takes to 
observe iPS cell colonies after induc-
tion of pluripotency, which varies from 
7 to 14 days in mouse cells and 14 to 28 
days in human cells. These complica-
tions constitute a “black box” in which 
the intermediate stages of reprogram-
ming are difficult to access. Neverthe-
less, current reprogramming efficien-
cies allow the use of end-point data, 
that is, the number of iPS cells properly 
reprogrammed can be assayed through 
the expression of reporter genes in a 
quantitative manner. Further improve-
ments in the extent and efficiency of 
pluripotency induction (Yamanaka, 
2009 and references therein) will facili-
tate the use of iPS cells in basic biology 
studies. In addition, the development of 
readouts for early stages of reprogram-
ming may allow the process of iPS cell 
generation to be visualized and studied 
in real-time.
In summary, knowledge of the basic 
biology of pluripotency in early embryos 
and ES cells paved the way for the dis-
covery of iPS cells. The interplay between 
iPS and ES cell research extends beyond 
technical improvements to the method of 
iPS cell generation and is providing new 
insights into the regulation of pluripo-
tency. The iPS cell assay is a new quan-r Inc.titative tool to study the basic biology of 
reprogramming in vivo and to dissect the 
regulation of both the pluripotent and 
the differentiated cell state. The iPS cell 
assay should make important contribu-
tions to developmental biology, regen-
erative medicine, and cancer biology.
ACknowledgmenTS
I thank the Santos lab, R. Blelloch, J. Ramalho-
Santos, M. Conti, B. Bruneau, J. Reiter, and S. 
Fisher for helpful comments and M. Grskovic for 
help with the figure. M.R.-S. is funded by an NIH 
Director’s New Innovator Award, the California In-
stitute for Regenerative Medicine, and the Juvenile 
Diabetes Research Foundation.
ReFeRenCeS
Blelloch, R., Venere, M., Yen, J., and Ramalho-
Santos, M. (2007). Cell Stem Cell 1, 245–247.
Feng, B., Jiang, J., Kraus, P., Ng, J.H., Heng, J.C., 
Chan, Y.S., Yaw, L.P., Zhang, W., Loh, Y.H., Han, 
J., et al. (2009). Nat. Cell Biol. 11, 197–203.
Gaspar-Maia, A., Alajem, A., Polesso, F., Sridha-
ran, R., Mason, M., Heidersbach, A., Ramalho-
Santos, J., McManus, M.T., Plath, K., Meshorer, 
E., and Ramalho-Santos, M. (2009). Nature. Pub-
lished online July 8, 2009. 10.1038/nature08212.
Gurdon, J.B. (1962). J. Embryol. Exp. Morphol. 10, 
622–640.
Hochedlinger, K., and Plath, K. (2009). Develop-
ment 136, 509–523.
Jiang, J., Chan, Y.S., Loh, Y.H., Cai, J., Tong, G.Q., 
Lim, C.A., Robson, P., Zhong, S., and Ng, H.H. 
(2008). Nat. Cell Biol. 10, 353–360.
Judson, R.L., Babiarz, J.E., Venere, M., and Blel-
loch, R. (2009). Nat. Biotechnol. 27, 459–461.
Kaji, K., Caballero, I.M., MacLeod, R., Nichols, J., 
Wilson, V.A., and Hendrich, B. (2006). Nat. Cell 
Biol. 8, 285–292.
Mikkelsen, T.S., Hanna, J., Zhang, X., Ku, M., Wer-
nig, M., Schorderet, P., Bernstein, B.E., Jaenisch, 
R., Lander, E.S., and Meissner, A. (2008). Nature 
454, 49–55.
Sridharan, R., Tchieu, J., Mason, M.J., Yachechko, 
R., Kuoy, E., Horvath, S., Zhou, Q., and Plath, K. 
(2009). Cell 136, 364–377.
Takahashi, K., and Yamanaka, S. (2006). Cell 126, 
663–676.
Wong, D.J., Liu, H., Ridky, T.W., Cassarino, D., Se-
gal, E., and Chang, H.Y. (2008). Cell Stem Cell 2, 
333–344.
Yamanaka, S. (2009). Cell 137, 13–17.
Zhao, Y., Yin, X., Qin, H., Zhu, F., Liu, H., Yang, 
W., Zhang, Q., Xiang, C., Hou, P., Song, Z., et al. 
(2008). Cell Stem Cell 3, 475–479.
Zhou, Q., and Melton, D.A. (2008). Cell Stem Cell 
3, 382–388.
